IL2 immunoconjugate formulations
By optimizing fermentation conditions and downstream processes, the percentage of glycosylated IL2 is reduced, and the T-cell activation activity of IL2 immunoconjugates is improved, which solves the problem of excessive glycosylation of IL2 in eukaryotic cells, and provides a stable, Effective cancer treatment preparation.
Patent Information
- Application Number
- CN202380029100.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2022-03-23
- Filing Date
- 2023-03-22
- Publication Date
- 2024-12-03
AI Technical Summary
When IL2 is produced in eukaryotic cells, excessive glycosylation levels lead to increased immunogenicity of the formulation and production instability, affecting its application in cancer treatment.
A production method was designed to reduce the percentage of glycosylated IL2 through fermentation conditions and downstream process optimization, so that it accounts for ≤25% of the total IL2 in the IL2 immunoconjugates, and glycosylation was determined by mass spectrometry. Type and percentage to ensure high yield and purity of the formulation.
The high yield and high purity of low glycosylated IL2 were achieved, which significantly improved T cell activation activity, solved the problems of immunogenicity and production instability caused by excessive glycosylated IL2, and provided an effective cancer treatment preparation.
Smart Images

Figure BDA0005052011820000101 
Figure BDA0005052011820000111 
Figure BDA0005052011820000121
Abstract
Description
[0001] This application claims priority from European patent application No. 22163911.5 filed on March 23, 2022, the contents and elements of which are incorporated herein by reference for all purposes. Technical Field
[0002] The present invention relates to a preparation, in particular a pharmaceutical preparation, comprising a non-glycosylated IL2 immunoconjugate and a glycosylated IL2 immunoconjugate, wherein the percentage of the glycosylated IL2 immunoconjugate in the preparation is low, preferably 25% or less of the total IL2 immunoconjugate. The preparation is shown to have increased T cell activation activity relative to a preparation with a higher percentage of glycosylated IL2 immunoconjugate. The preparation can be used in the treatment of cancer in human patients. Background Art
[0003] Applicants describe immunoconjugates comprising human IL2 fused to the antibody L19 ("L19-IL2") in WO 2001 / 062298, which is hereby incorporated by reference in its entirety. L19 (U.S. Pat. No. 8,097,254) specifically binds to the ED-B domain of the fibronectin isoform B-FN, one of the best-known markers of angiogenesis. ED-B is an additional domain of 91 amino acids found in the B-FN isoform. ED-B accumulates around new vascular structures in invasive tumors and other tissues undergoing angiogenesis (such as the endometrium in the proliferative phase and some ocular structures in pathological conditions), but is otherwise undetectable in normal adult tissues. The applicants have previously described a number of uses for L19-IL2, in particular its use in the treatment of human cancer, in WO 2007 / 115837, WO 2009 / 089858, WO 2013 / 010749, WO 2013 / 045125, WO 2018 / 154517, WO 2019 / 185792, WO2020 / 070150, which applications are hereby incorporated by reference in their entirety.
[0004] One difficulty in producing L19-IL2 for administration to human patients is the extensive glycosylation when producing IL2 in eukaryotic cells. Specifically, it has been previously demonstrated that producing human IL2 in Chinese hamster ovary (CHO) cells results in high levels of glycosylation, with glycosylated IL2 greatly exceeding non-glycosylated IL2 (Ferrara et al., FEBS Letters (1987), 226, 47). U.S. Patent No. 5,417,970 similarly reports that expression of recombinant human IL2 in CHO cells results in about 50% of the total IL2 present in the preparation being glycosylated.
[0005] High levels of glycosylation pose challenges in terms of batch-to-batch reproducibility for good manufacturing practice (GMP) production, increased immunogenicity, and suboptimal pharmacokinetics when preparing products for industrial development. Durocher and Butler, Current Opinion Biotechnol (2009), 20, 770 explain that glycan structures may be immunogenic, and immunogenicity may reduce the efficacy of biological agents due to rapid clearance by the immune system. Planinc et al., Analytica Chimica Acta (2016) 13, 27 similarly confirm the importance of low abundance of glycans because of their potential immunogenicity. Leepenies and Seeberger Nature Biotechnol. (2016), 32, 443 further comment that heterogeneous glycosylation may lead to batch-to-batch differences in efficacy or pharmacokinetics.
[0006] Although it is theoretically possible to obtain non-glycosylated proteins by recombinant expression in prokaryotic cells, this is not possible in the context of complex proteins such as L19-IL2, which forms large 80 KDa non-covalent homodimers in solution.
[0007] Despite the above immunogenicity and GMP compliance challenges associated with high levels of glycosylation, it is believed in the art that high levels of glycosylation in IL2 molecules are beneficial for promoting T cell proliferation. For example, Pawelec et al., Immunobiology (1987), 174, 67, compared glycosylated IL2 purified from natural sources with non-glycosylated IL2 produced in E. coli (E. Coli), and concluded that glycosylated IL2 was superior to non-glycosylated IL2 for the propagation of human T cells (see, e.g., Abstract).
[0008] In view of the foregoing, there remains a need in the art for preparations of L19-IL2 having favorable characteristics in terms of both (i) immunogenicity and (ii) T cell activation activity, for example, for use in the treatment of cancer. Summary of the invention
[0009] The inventors have designed a method for producing a preparation of L19-IL2 that results in a high yield and, surprisingly, a low percentage of glycosylated L19-IL2 in the resulting preparation. Specifically, the percentage of glycosylated L19-IL2 in the preparation is reported to be between about 16.5% and 18.5%, with an average of 17% of L19-IL2 being glycosylated ( FIG. 4 ). This is very surprising in view of the high glycosylation rates reported in the literature when IL2 is produced in eukaryotic cells (see discussion above). Previously described methods for producing L19-IL2 conjugates do not provide any information on glycosylation levels (Carnemolla et al. Blood (2002) 99, 1659).
[0010] Furthermore, when a formulation comprising a low percentage of glycosylated L19-IL2 (“IPO L19-IL2”) was compared to a formulation comprising a high percentage of glycosylated L19-IL2 (“IPER L19-IL2”), the formulation with a low percentage of glycosylated L19-IL2 (“IPO L19-IL2”) unexpectedly resulted in superior T cell activation ( Fig.11 ). This is very surprising given that literature reports that glycosylation of IL2 leads to superior T cell activation (see discussion above).
[0011] Without wishing to be bound by theory, it is believed that the fermentation conditions used to prepare the L19-IL2 conjugates described herein resulted in the observed low levels of glycosylated species. In particular, the inventors were able to demonstrate that differences in downstream processes and process parameters did not affect the percentage of glycosylated L19-IL2 present in the final formulation.
[0012] In view of the above, it is expected that the low percentage of glycosylated L19-IL2 in the preparations obtained by the production method designed by the inventors will have advantageous properties when used in the treatment of human patients, compared to L19-IL2 preparations containing a higher percentage of glycosylated L19-IL2. Such advantageous properties include increased T cell activation activity.
[0013] Therefore, in a first aspect, the present invention provides a formulation comprising:
[0014] (i) aglycosylated IL2 immunoconjugate; and
[0015] (ii) glycosylated IL2 immunoconjugate;
[0016] wherein the IL2 immunoconjugate comprises human IL2 conjugated to an antibody molecule, the antibody molecule comprising the L19 complementarity determining region (CDR) shown in SEQ ID NOs 1 to 6, and
[0017] wherein the percentage of the glycosylated IL2 immunoconjugate in the preparation is ≤25% of the total IL2 immunoconjugate.
[0018] In a preferred embodiment, the antibody molecule in the IL2 immunoconjugate comprises the L19 VH domain shown in SEQ ID NO: 7 and the L19 VL domain shown in SEQ ID NO: 9. More preferably, the antibody molecule has the sequence of the L19 antibody in scFv form shown in SEQ ID NO: 10. Most preferably, the IL2 immunoconjugate consists of or comprises the L19-IL2 sequence shown in SEQ ID NO: 13.
[0019] The IL2 is preferably human IL2. Most preferably, the IL2 has the sequence shown in SEQ ID NO:11.
[0020] Therefore, in a preferred embodiment, the present invention provides a preparation comprising:
[0021] (i) non-glycosylated L19-IL2; and
[0022] (ii) glycosylated L19-IL2;
[0023] wherein the L19-IL2 comprises or consists of the sequence shown in SEQ ID NO: 13; and
[0024] The percentage of glycosylated L19-IL2 in the preparation is ≤25% of the total L19-IL2.
[0025] The percentage of glycosylated IL2 immunoconjugate to total IL2 immunoconjugate in the formulation is preferably ≤25%, ≤24%, ≤23%, ≤22%, ≤21%, ≤20%, ≤19% or ≤18.5%, with lower glycosylation % being preferred for the reasons explained above.
[0026] The percentage of glycosylated IL2 immunoconjugate to total IL2 immunoconjugate in the formulation may be ≥2%, ≥5%, ≥10% or ≥15%.
[0027] For example, the percentage of glycosylated IL2 immunoconjugates to total IL2 immunoconjugates in the formulation may be ≥ 2% and ≤ 20%.
[0028] The glycosylated IL2 immunoconjugate comprises O-linked glycosylation at the serine at position 3 of IL2, wherein the IL2 has the sequence shown in SEQ ID NO: 11. In the case where the IL2 immunoconjugate is L19-IL2 and comprises or consists of the sequence shown in SEQ ID NO: 13, the glycosylated L19-IL2 preferably comprises O-linked glycosylation on the serine at position 256 of SEQ ID NO: 13. The O-linked glycosylation may be linear or branched. In the IL2 immunoconjugate with linear O-linked glycosylation, the O-linked glycosylation preferably comprises one core of hexose N-acetyl-hexose 1 plus 1 N-glycolylneuraminic acid, while in the IL2 immunoconjugate comprising branched O-linked glycosylation, the O-linked glycosylation preferably comprises one core of hexose N-acetyl-hexose 1 plus 2 N-glycolylneuraminic acid residues. More preferably, the O-linked glycosylation is HexNAc1Hex1NeuGc1 or HexNAc1Hex1NeuGc2. In one example, the O-linked glycosylation is Neu5Gcα2-3Galβ1-3GalNAcC1S(3)1 or Neu5Gcα2-3Galβ1-3(Neu5Gcα2-6)GalN AcC1S(3,6)2.
[0029] In a preferred embodiment, the IL2 immunoconjugate is not glycosylated at any other position in the IL2 sequence.
[0030] In a preferred embodiment, the present invention provides a preparation comprising:
[0031] (i) aglycosylated IL2 immunoconjugate; and
[0032] (ii) glycosylated IL2 immunoconjugate;
[0033] wherein the L19-IL2 comprises or consists of the sequence shown in SEQ ID NO: 13, wherein the percentage of glycosylated L19-IL2 in the preparation to total L19-IL2 is ≤ 20%, and
[0034] The preparation has higher T cell activation activity compared to a preparation in which the percentage of glycosylated L19-IL2 in the total L19-IL2 is 45% or more, preferably 45%.
[0035] Methods for determining the type and percentage of glycosylated IL2 immunoconjugate in a preparation of IL2 immunoconjugate are known to the skilled artisan and include mass spectrometry, in particular intact mass analysis, as described herein.
[0036] In addition to the active ingredient (glycosylated and non-glycosylated IL2 immunoconjugates), the pharmaceutical preparations of the present invention may further comprise pharmaceutically acceptable excipients, carriers, buffers, stabilizers or other materials well known to those skilled in the art and suitable for administration to human patients. Suitable materials should be non-toxic and should not interfere with the efficacy of the active ingredient. For injection at the tumor site, the pharmaceutical preparation may be in the form of a parenterally acceptable aqueous solution that is pyrogen-free and has a suitable pH, isotonicity and stability.
[0037] The pharmaceutical preparation of the present invention can be used in a method for treating cancer in a patient. A method for treating cancer is also provided, the method comprising administering a therapeutically effective amount of the pharmaceutical preparation of the present invention to the patient. Similarly provided is the use of the pharmaceutical preparation of the present invention in the manufacture of a medicament for treating cancer. The patient is preferably a human patient.
[0038] Cancers that can be treated using the pharmaceutical formulations of the present invention include solid cancers, such as skin cancer, kidney cancer, pancreatic cancer, non-small cell lung cancer, diffuse large B-cell lymphoma (DLBCL), basal cell carcinoma, or cutaneous squamous cell carcinoma.
[0039] The present invention includes any combination of the described aspects and preferred features, except where such a combination is expressly impermissible or explicitly avoided. BRIEF DESCRIPTION OF THE DRAWINGS
[0040] Embodiments and experiments illustrating the principles of the present invention will now be discussed with reference to the accompanying drawings, in which:
[0041] Figure 1 A general overview of the L19-IL2 production process for obtaining a pharmaceutical formulation of the invention comprising a low percentage of glycosylated L19-IL2 is shown.
[0042] Figure 2A : Two-dimensional SDS-PAGE analysis of a pharmaceutical preparation containing a low percentage of glycosylated L19-IL2 confirmed the purity of the post-production sample, as well as the molecular weight (about 42 KDa) and isoelectric point (about 7.7) of L19-IL2. Three spots are visible: non-glycosylated L19-IL2 (spot 1), mono-glycosylated L19-IL2 (spot 2), and di-glycosylated L19-IL2 (spot 3). Spot 1 (non-glycosylated L19-IL2) is the most obvious, while spots 2 and 3 are almost invisible, indicating that the abundance of glycosylated L19-IL2 in the preparation is very low. Figure 2B : Milligrams of purified L19-IL2 per liter of fermentation culture recovered from five production batches.
[0043] Figure 3A: shows a deconvoluted spectrum of mass spectrometry analysis of a L19-IL2 preparation containing a low percentage of glycosylated L19-IL2 prepared according to the methods described herein. The main peak (1) at 42022 Da corresponds to the non-glycosylated L19-IL2 protein, while the peak (2) at 42695 Da corresponds to the L19-IL2 variant with the glycan HexNAc1Hex1NeuGc1, and the peak (3) at 43001 Da corresponds to the L19-IL2 variant with the glycan HexNAc1Hex1NeuGc2. The other minor peaks are irrelevant: the small peak at 41978 Da is a typical MS artifact, corresponding to L19-IL2 without a CO2 group. Another small peak at 42120 Da corresponds to L19-IL2 coupled to the phosphate group of the buffer. Figure 3B : (Not according to the claimed invention; included for comparison purposes only) shows a deconvoluted spectrum of a mass spectrometry analysis of an L19-IL2 preparation containing a high percentage of glycosylated L19-IL2. The peak (1) at 42022 Da corresponds to the non-glycosylated L19-IL2 protein, while the peak (2) at 42678 Da corresponds to the L19-IL2 variant with the glycan HexNAc1Hex1NeuAc1, the peak (3) at 42970 Da corresponds to the L19-IL2 variant with the glycan HexNAc1Hex1NeuAc2, and the peak (4) at 4335 corresponds to the L19-IL2 variant with the glycan HexNAc2Hex2NeuAc2. The other minor peaks are irrelevant: the small peak at 41978 Da is a typical MS artifact, corresponding to L19-IL2 without a CO2 group. Another small peak at 42120 Da corresponds to L19-IL2 coupled to the phosphate group of the buffer.
[0044] Figure 4A : Shows the percentage of non-glycosylated L19-IL2, mono-glycosylated L19-IL2 and di-glycosylated L19-IL2 in different production batches of pharmaceutical formulations prepared using the methods described herein. In five production batches using the methods described herein, glycosylated L19-IL2 in the formulation never exceeded 20% of the total L19-IL2, with the average percentage of glycosylated L19-IL2 in the formulation being 17.06%. Figure 4B : The percentages of non-glycosylated L19-IL2 and glycosylated L19-IL2 produced according to a standard protocol (i.e., not according to the claimed invention; included only for comparison purposes) are shown. In this case, non-glycosylated L19-IL2 and glycosylated L19-IL2 each formed 45%-50% of the total L19-IL2 in the formulation.
[0045] Figure 5Shown is the MS1 spectrum of the glycosylated peptide VEIKEFSSSSGSSSSGSSSSGAPT(+HexNAc1Hex1NeuGc1)SSST K in a representative production batch of L19-IL2 formulation containing a low percentage of glycosylated L19-IL2. The detection of the 4+ charged ion at 853.6212 m / z is consistent with the presence of an additional NeuGc group on the HexNAc1Hex1 core attached to the threonine at position 24 of the peptide (which corresponds to the threonine at position 256 in the L19-IL2 conjugate).
[0046] Figure 6 The MS2 spectrum of the glycosylated peptide VEIKEFSSSSGSSSSGSSSSGAPT(+HexNAc1Hex1NeuGc1)SSST K in a representative production batch of L19-IL2 formulation containing a low percentage of glycosylated L19-IL2 is shown. The precursor ion at 853.62 m / z was isolated and HCD fragmented to generate this MS2 spectrum. Together with the expected y-ion list, the presence of two peaks at 290.08 m / z (NeuGc1-H2O) and 308.09 m / z (NeuGc1) confirms the presence of the NeuGc group on the peptide. This data further confirms the correct identification of the HexNAc1Hex1NeuGc1 group on the threonine at position 24 of the peptide (which corresponds to the threonine at position 256 in the L19-IL2 conjugate).
[0047] Figure 7 Shown is the MS1 spectrum of the glycosylated peptide VEIKEFSSSSGSSSSGSSSSGAPT(+HexNAc1Hex1NeuGc2)SSST K in a representative production batch of L19-IL2 formulation containing a low percentage of glycosylated L19-IL2. The detection of the 3+ charged ion at 1240.1882 m / z is consistent with the presence of two additional NeuGc groups on the HexNAc1Hex1 core attached to the threonine at position 24 of the peptide (which corresponds to the threonine at position 256 in the L19-IL2 conjugate).
[0048] Figure 8The MS2 spectrum of the glycosylated peptide VEIKEFSSSSGSSSSGSSSSGAPT(+HexNAc1Hex1NeuGc2)SSST K in a representative production batch of L19-IL2 formulations containing a low percentage of glycosylated L19-IL2 is shown. The precursor ion at 1240.18 m / z was isolated and HCD fragmented to generate this MS2 spectrum. Together with the expected y-ion list, the presence of two peaks at 290.08 m / z (NeuGc1-H2O) and 308.09 m / z (NeuGc1) confirms the presence of additional NeuGc groups on the peptide. This data further confirms the correct identification of the HexNAc1Hex1NeuGc2 group on the threonine at position 24 of the peptide (which corresponds to the threonine at position 256 in the L19-IL2 conjugate).
[0049] Fig. 9A and Fig. 9B Shown are diagrams describing the inoculum preparation and fermentation process (Upstream 1 and Upstream 2) for obtaining L19-IL2 preparations containing a low percentage of glycosylated L19-IL2.
[0050] Fig. 10A and Fig. 10B Shown are diagrams depicting the purification process steps (Downstream 1 and Downstream 2) for obtaining an L19-IL2 preparation containing a low percentage of glycosylated L19-IL2.
[0051] Fig.11 A T cell activation assay is shown, which compares an L19-IL2 preparation containing a low percentage of glycosylated L19-IL2 according to the present invention ("IPO L19IL2") with an L19-IL2 preparation containing a high percentage of glycosylated L19-IL2 prepared using a standard method ("IPER L19IL2"). This shows that the L19-IL2 preparation containing a low percentage of glycosylated L19-IL2 exhibits superior T cell activation activity (EC50 4.3pM) as compared to the L19-IL2 preparation containing a high percentage of glycosylated L19-IL2 (EC50 9.5pM). DETAILED DESCRIPTION
[0052] Various aspects and embodiments of the present invention will now be discussed with reference to the accompanying drawings. Other aspects and embodiments will be clear to those skilled in the art. All documents mentioned in this text are incorporated herein by reference.
[0053] The pharmaceutical composition of the present invention comprises an IL2 immunoconjugate, wherein the IL2 immunoconjugate comprises an antibody molecule comprising the L19 complementarity determining region (CDR) shown in SEQ ID NOs 1 to 6 and IL2.
[0054] The antibody molecule is preferably monoclonal.The antibody molecule may be human or humanized, but is preferably a human antibody molecule.
[0055] The antibody molecule may be isolated in the sense of being free of contaminants, such as antibodies and / or serum components that are capable of binding to other polypeptides.
[0056] The antibody molecule may be natural or partially or completely synthetically produced. For example, the antibody molecule may be a recombinant antibody molecule.
[0057] The antibody molecule can be an immunoglobulin or an antigen binding fragment thereof. For example, the antibody molecule can be an IgG, IgA, IgE or IgM molecule, preferably an IgG molecule, such as an IgG1, IgG2, IgG3 or IgG4 molecule, but more preferably an antigen binding fragment thereof. In a preferred embodiment, the antibody molecule comprises or consists of a single-chain Fv (scFv), a small immune protein, a double antibody, but most preferably an scFv.
[0058] The antibody molecule preferably comprises the L19 VH domain shown in SEQ ID NO: 7 and / or the L19 VL domain shown in SEQ ID NO: 9. More preferably, the antibody molecule has the sequence of the L19 antibody in scFv form shown in SEQ ID NO: 10.
[0059] In the case where the antibody molecule is a scFv, the VH and VL domains of the antibody are preferably connected by a linker of 12 to 20 amino acids. For example, the VH and VL domains can be connected by an amino acid linker of 12, 13, 14, 15, 16, 17, 18, 19 or 20 amino acids in length. Suitable linker sequences are known in the art and include the linker sequence shown in SEQ ID NO:8.
[0060] The IL2 is preferably human IL2. Most preferably, the IL2 has the sequence shown in SEQ ID NO:11.
[0061] The antibody molecule (e.g., scFv or IgG) and IL2 can be directly linked to each other, for example, by any suitable chemical bond, but are preferably linked via a peptide linker. The chemical bond can be, for example, a covalent bond or an ionic bond. Examples of covalent bonds include peptide bonds (amide bonds) and disulfide bonds.
[0062] In the case where IL2 is linked to the antibody molecule via a peptide linker, the peptide linker can be a short (2-30, preferably 10-20) residue stretch of amino acids. Suitable examples of peptide linker sequences are known in the art. One or more different linkers can be used. An exemplary linker sequence is shown in SEQ ID NO 12. In one embodiment, the linker can be a cleavable linker.
[0063] In case the antibody molecule and IL2 are linked via a peptide bond or a peptide linker, the conjugate can be produced (secreted) as a single-chain polypeptide, such as a fusion protein.
[0064] In a preferred embodiment, IL2 is conjugated to the C-terminus of an antibody molecule in the form of a scFv.Most preferably, the IL2 immunoconjugate consists of or comprises the sequence of L19-IL2 shown in SEQ ID NO:13.
[0065] The IL2 in the glycosylated IL2 immunoconjugate contained in the pharmaceutical formulation of the present invention preferably comprises O-linked glycosylation on the serine at position 3 of the IL2 sequence shown in SEQ ID NO: 11. In case the IL2 immunoconjugate is L19-IL2 and comprises or consists of the sequence shown in SEQ ID NO: 13, the glycosylated L19-IL2 preferably comprises O-linked glycosylation on the serine at position 256 of SEQ ID NO: 13. In a preferred embodiment, the glycosylated IL2 immunoconjugate is not glycosylated at any other position of the IL2 sequence.
[0066] The IL2 in the glycosylated IL2 immunoconjugate may be monoglycosylated or diglycosylated. In the monoglycosylated IL2 immunoconjugate, the O-linked glycosylation is preferably HexNAc1Hex1NeuGc1, while in the diglycosylated IL2 immunoconjugate, the O-linked glycosylation is preferably HexNAc1Hex1NeuGc2. In addition to the non-glycosylated IL2 immunoconjugate, the pharmaceutical preparation of the present invention generally also contains both the monoglycosylated IL2 immunoconjugate and the diglycosylated IL2 immunoconjugate.
[0067] In the glycosylated L19-IL2 immunoconjugate contained in the pharmaceutical preparation of the present invention, L19 is not glycosylated. That is, in the glycosylated L19-IL2 immunoconjugate contained in the pharmaceutical preparation of the present invention, only IL2 is glycosylated.
[0068] The percentage of glycosylated IL2 immunoconjugate to total IL2 immunoconjugate in the pharmaceutical formulation of the present invention is preferably ≤25%, ≤24.5%, ≤24%, ≤23.5%, ≤23%, ≤22.5%, ≤22%, ≤21.5%, ≤21%, ≤20.5%, ≤20%, ≤19.5%, ≤19% or ≤18.5%, with lower glycosylation percentages being preferred for the reasons described above. In a preferred embodiment, the glycosylation percentage is ≤20%. In an alternative preferred embodiment, the glycosylation percentage is ≤19.5%. In another alternative preferred embodiment, the glycosylation percentage is ≤19%. In yet another alternative preferred embodiment, the glycosylation percentage is ≤18.5%.
[0069] The percentage of glycosylated IL2 immunoconjugate to total IL2 immunoconjugate in the formulation may be ≥2%, ≥3%, ≥4%, ≥5%, ≥6%, ≥7%, ≥8%, ≥9%, ≥10%, ≥11%, ≥12%, ≥13%, ≥14%, ≥15% or ≥16%. This does not include IL2 immunoconjugate preparations made in bacterial cells, which are not glycosylated.
[0070] For example, the percentage of glycosylated IL2 immunoconjugates to the total IL2 immunoconjugates in the formulation may be ≥2% and ≤20%, ≥2% and ≤19.5%, ≥2% and ≤19%, or ≥2% and ≤18.5%. Alternatively, the percentage of glycosylated IL2 immunoconjugates to the total IL2 immunoconjugates in the formulation may be ≥5% and ≤20%, ≥5% and ≤19.5%, ≥5% and ≤19%, or ≥5% and ≤18.5%. As another alternative, the percentage of glycosylated IL2 immunoconjugates to the total IL2 immunoconjugates in the formulation may be ≥10% and ≤20%, ≥10% and ≤19.5%, ≥10% and ≤19%, or ≥10% and ≤18.5%.
[0071] Methods for measuring the percentage of glycosylated IL2 immunoconjugates present in a pharmaceutical composition and determining the type of glycosylation present are known in the art and include mass spectrometry, particularly intact mass analysis. Exemplary methods are detailed in Example 3. The results of such analysis are shown in Figures 3 to 4. Figure 8 middle.
[0072] In addition to the glycosylated and non-glycosylated IL2 immunoconjugates as shown in the claims, the pharmaceutical formulations of the present invention may also include pharmaceutically acceptable excipients, carriers, buffers, stabilizers or other materials known to those skilled in the art and suitable for administration to human patients. The pharmaceutical composition may include a buffer composition as disclosed in WO 2018 / 011404. In particular, the pharmaceutical composition may include the glycosylated and non-glycosylated IL2 immunoconjugates as described in the claims dissolved in a phosphate buffer, the phosphate buffer comprising NaH2PO4 at a concentration of 1-50 mM, NaCl at a concentration of 1-50 mM, KCl at a concentration of 1-2 mM, mannitol at a concentration of 50-200 mM, polysorbate 80 at a concentration of 0.05%-0.2% (v / v) or 0.05%-0.3%, glycerol at a concentration of 0.5%-2%, and a pH of 5.5-7.0. Optionally, the phosphate buffer may further comprise EDTA at a concentration of 1-20 mM, but this is not preferred.
[0073] NaH2PO4 may be present in a concentration selected from the range of 2-25mM, 3-20mM, more preferably 5-15mM. Most preferably, NaH2PO4 is present at 6.7mM or about 6.7mM. NaCl may be present in a concentration selected from the range of 5-40mM or 10-30mM, or more preferably 15-25mM. Most preferably, NaCl is present at 20mM or about 20mM. KCl may be present in a concentration selected from the range of 1.2-2.0mM, more preferably 1.5-1.8mM. Most preferably, KCl is present at 1.8mM or about 1.8mM.
[0074] Mannitol can be present in a concentration selected from the range of 80-180mM, or more preferably 100-150mM. Most preferably, mannitol is present at 133mM or about 133mM. Polysorbate 80 can be present in a concentration (expressed in v / v) selected from the range of 0.1%-0.3%, 0.07%-0.18%, or more preferably 0.08%-0.15%. Polysorbate 80 can be present at 0.1% (v / v) or about 0.1% (v / v). Preferably, polysorbate 80 is present at 0.3% (v / v) or about 0.3% (v / v).
[0075] Glycerol can be present in a concentration selected from the range of 0.7%-1.8%, or more preferably 0.8%-1.5%. Most preferably, glycerol is present at 1% (w / v) or about 1% (w / v). EDTA can be present in a concentration selected from the range of 2-15mM, or more preferably 3-10mM or 6-9mM. Most preferably, EDTA is present at 5mM or about 5mM. The pH is preferably 6.0-6.8, more preferably 6.1-6.5mM or 6.2-6.4. Most preferably, the pH is 6.3 or about 6.3. In a preferred embodiment, EDTA is not present.
[0076] In addition to the glycosylated and non-glycosylated IL2 immunoconjugates as claimed in the claims, the pharmaceutical formulation of the present invention may also comprise 6.7 mM NaH2PO4, 20 mM NaCl, 1.8 mM KCl, 133 mM mannitol, 0.1% polysorbate 80 (v / v), 1% glycerol (w / v) and 5 mM EDTA, and the pH is 6.3. Preferably, in addition to the glycosylated and non-glycosylated IL2 immunoconjugates as claimed in the claims, the pharmaceutical formulation of the present invention may also comprise 6.7 mM NaH2PO4, 20 mM NaCl, 1.8 mM KCl, 133 mM mannitol, 0.3% polysorbate 80 (v / v), 1% glycerol (w / v), and the pH is 6.3.
[0077] Most preferably, the pharmaceutical formulation of the present invention may comprise, in addition to the glycosylated and non-glycosylated IL2 immunoconjugates as indicated in the claims, 6.7 mM NaH2PO4, 20 mM NaCl, 1.8 mM KCl, 133 mM mannitol, 0.1%-0.3% polysorbate 80 (v / v) and 1% glycerol (w / v), and has a pH of 6.3.
[0078] Alternatively, in addition to the glycosylated and non-glycosylated IL2 immunoconjugates as set forth in the claims, the pharmaceutical formulations of the present invention may also comprise about 6.7 mM NaH2PO4, about 20 mM NaCl, about 1.8 mM KCl, about 133 mM mannitol, about 0.1% polysorbate 80 (v / v), about 1% glycerol (w / v) and about 5 mM EDTA, and the pH is about 6.3. In a preferred alternative embodiment, in addition to the glycosylated and non-glycosylated IL2 immunoconjugates as set forth in the claims, the pharmaceutical formulations of the present invention may also comprise about 6.7 mM NaH2PO4, about 20 mM NaCl, about 1.8 mM KCl, about 133 mM mannitol, about 0.3% polysorbate 80 (v / v), about 1% glycerol (w / v) and about 5 mM EDTA, and the pH is about 6.3.
[0079] As a further alternative, in addition to the glycosylated and non-glycosylated IL2 immunoconjugates as set forth in the claims, the pharmaceutical formulations of the present invention may also comprise about 6.7 mM NaH2PO4, about 20 mM NaCl, about 1.8 mM KCl, about 133 mM mannitol, about 0.1-0.3% polysorbate 80 (v / v) and about 1% glycerol (w / v), and have a pH of about 6.3.
[0080] The preparation of the present invention has higher T cell activation activity than a preparation in which the percentage of glycosylated L19-IL2 to total L19-IL2 in the preparation is 45% or more, preferably 45%.
[0081] As used herein, "T cell activation activity" refers to the ability of L19-IL2 preparations to enhance T cell proliferation. The T cell activation activity of the L19-IL2 conjugate can be expressed as a half-maximal effective concentration (EC50).
[0082] The half maximum effective concentration (EC50) is a measure of effectiveness in inducing a specific biological or biochemical function. EC50 is a quantitative measure that indicates how much agonist is needed to increase the activity of a given biological process or component of a process (such as an enzyme, cell, cell receptor, or microorganism) by half. Methods for determining EC50 in vitro and in vivo are known in the art. In the context of the present invention, EC50 can refer to the amount of L19-IL2 required to increase the proliferation of a T cell population (such as a population of CTLL2 cells) by half.
[0083] The formulations of the invention preferably have a half-maximal effective concentration (EC50) of at most 4.3pM, 4.4pM, 4.5pM, 5pM, 5.5pM or 6pM, or a lower EC50. In the context of enhancing T cell population proliferation, the EC50 of the formulation (such as L19-IL2 formulation) can be determined by T cell activity assay (such as CTLL2 T cell activity assay), for example as described in detail in Example 5.
[0084] In some embodiments, the pharmaceutical formulations of the present invention may be administered alone or in combination with other therapies, either simultaneously or sequentially, depending on the condition to be treated.
[0085] Treatment involving the pharmaceutical preparation of the present invention may include administering a second anticancer therapy. Many suitable anticancer therapies are known in the art. For example, L19-IL2 has been successfully used in anticancer therapy when administered in combination with stereotactic ablative radiotherapy (SABR) or with an anti-PD-1 therapeutic agent (such as an anti-PD-1 antibody). Clinical trials of these combinations are ongoing. Promising anticancer effects of combined administration of L19-IL2 and L19-TNFα have also been reported (WO 2018 / 011404). This is a supplement to the anticancer effects demonstrated by L19-IL2 monotherapy.
[0086] Therefore, the pharmaceutical preparation of the present invention can be used in a method for treating cancer in a patient, wherein the method further comprises administering to the patient a second anticancer therapeutic selected from the following: radiation therapy, preferably stereotactic ablative radiation therapy (SABR); a radiolabeled conjugate, preferably a conjugate labeled with lutetium-177; a checkpoint inhibitor, such as an anti-PD-1 therapeutic agent, preferably an anti-PD-1 antibody; L19-TNFα, or L19-TNFα and an anti-PD-1 therapeutic agent. Administration of the pharmaceutical preparation of the present invention and a second anticancer therapy to a patient can be performed simultaneously or sequentially, wherein simultaneous administration refers to administration in the same treatment cycle but not necessarily on the same day.
[0087] The pharmaceutical formulation of the invention and the second anticancer therapy may be provided as a combined formulation, but are preferably provided as separate formulations to allow simultaneous or sequential administration. Where the treatment further involves radiotherapy, this radiotherapy will have to be administered separately from the pharmaceutical formulation of the invention, but administration may still be simultaneous.
[0088] Other treatments that may be used in combination with the pharmaceutical formulations of the invention include administration of appropriate doses of pain relief drugs such as nonsteroidal anti-inflammatory drugs (e.g., aspirin, acetaminophen, ibuprofen, or ketoprofen) or opioids (such as morphine) or antiemetics.
[0089] In the case of using the pharmaceutical preparation of the present invention for cancer treatment, it can be injected parenterally. In one embodiment, the pharmaceutical preparation of the present invention is injected (preferably by intratumoral injection) at the tumor site. Peritumoral injection (e.g., local intradermal injection) is another suitable method for local application of the pharmaceutical preparation of the present invention to the tumor site. In some embodiments, the pharmaceutical preparation of the present invention can be administered by infusion, e.g., intravenous infusion.
[0090] Cancer treatment according to the present invention may include complete eradication of a tumor. The disappearance of any evidence of a significant tumor after termination of treatment represents complete treatment of the tumor. The disappearance of a tumor may be determined when the tumor has no discernible volume or is no longer visible. Treatment may include treatment to eradicate a tumor and to prevent tumor regrowth.
[0091] After administration of the pharmaceutical preparation of the invention, the patient is preferably monitored during a follow-up period of at least one month, preferably at least six months or at least one year. During the follow-up period, the disappearance of the tumor and the absence of tumor regrowth can be observed. The absence of tumor regrowth can be observed.
[0092] The amount of L19-IL2 administered to the patient by the administration of the pharmaceutical preparation of the present invention will depend, among other things, on the size and nature of the tumor. The determination of a suitable dose is within the capabilities of a skilled practitioner. Suitable doses are disclosed in WO 2018 / 011404. For example, the dose of L19-IL2 may be in the following range: 20 μg-3 mg, such as 100-2,500 μg, 300-2,000 μg, or between 500-1,800 μg. Preferably, the dose of L19-IL2 is in the range of 2 mg to 3 mg, such as 2 mg to 2.5. Most preferably, the dose of L19-IL2 is 2.17 mg. The dose of L19-IL2 may alternatively be expressed in international units (IU). 2.17 mg L19-IL2 is equivalent to 13 million IU L19-IL2. These are examples only, and different doses may be used.
[0093] The pharmaceutical preparation of the present invention can be used in a method for treating cancer. The cancer can be a solid tumor. In a preferred embodiment, the cancer is selected from skin cancer, kidney cancer, pancreatic cancer, non-small cell lung cancer, diffuse large B-cell lymphoma (DLBCL), basal cell carcinoma or cutaneous squamous cell carcinoma. The cancer can be metastatic or non-metastatic.
[0094] In the case where the cancer to be treated with the pharmaceutical preparation of the present invention is skin cancer, the pharmaceutical preparation is preferably administered together with L19-TNFα. L19-TNFα preferably comprises or consists of the sequence shown in SEQ ID NO: 14. The details of this therapy are disclosed in WO 2013 / 045125 and WO 2018 / 011404, which are hereby incorporated by reference in their entirety. Therefore, the pharmaceutical preparation of the present invention can be used in a method for treating a patient's skin cancer (such as malignant melanoma or non-melanoma skin cancer, but preferably malignant melanoma), wherein the method further comprises administering L19-TNFα to the patient. Administration can be performed by injection at the tumor site, in particular by intratumoral injection. In the case of intratumoral injection, the patient can be treated once a week with 13 million IU of L19-IL2 (equivalent to 2.17 mg of L19-IL2) and 400 μg of L19-TNFα for one to four weeks, for example, for one, two, three or four consecutive weeks. The dose may be administered as a single intratumoral injection, or the dose may be divided into multiple intratumoral injections administered to the same tumor. In selected cases, the dose may be halved to 1.08 mg L19-IL2 and 200 μg L19-TNFα.
[0095] As used herein, an L19-IL2 preparation comprising a "low percentage" of glycosylated L19-IL2 refers to a preparation in which the percentage of glycosylated L19-IL2 in the preparation is ≤ 25% of the total L19-IL2.
[0096] As used herein, an L19-IL2 preparation comprising a "high percentage" of glycosylated L19-IL2 refers to a preparation in which the percentage of glycosylated L19-IL2 in the preparation is ≥ 40% of the total L19-IL2.
[0097] The features disclosed in the foregoing description, or the attached claims, or the drawings are expressed in their specific forms or in terms of means for performing the disclosed functions, or methods or processes for obtaining the disclosed results, and may be used alone or in any combination of such features as appropriate to implement the present invention in its diverse forms.
[0098] Although the present invention has been described in conjunction with the above exemplary embodiments, many equivalent modifications and variations will be clear to those skilled in the art when this disclosure is given. Therefore, the exemplary embodiments of the present invention described above are considered to be illustrative rather than restrictive. Various changes may be made to the described embodiments without departing from the spirit and scope of the present invention.
[0099] For the avoidance of any doubt, any theoretical explanations provided herein are intended to improve the reader's understanding. The inventors do not wish to be bound by any of these theoretical explanations.
[0100] Any section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described.
[0101] Throughout the specification, including the following claims, unless the context requires otherwise, the words "comprise" and "include", and variations such as "comprises", "comprising" and "including", will be understood to imply the inclusion of stated integers or steps or groups of integers or steps but not the exclusion of any other integers or steps or groups of integers or steps.
[0102] It must be noted that, as used in the specification and the appended claims, the singular forms "a", "an", and "the" include plural referents unless the context clearly dictates otherwise. Ranges may be expressed herein as from "about" one particular value and / or to "about" another particular value. When such a range is expressed, another embodiment includes from the one particular value and / or to the other particular value. Similarly, when a value is expressed as an approximation by using the antecedent "about", it will be understood that the specific value forms another embodiment. The term "about" in relation to a numerical value is optional and means, for example, + / - 10%.
[0103] Example
[0104] Example 1 - Method for producing a L19-IL2 formulation containing a low percentage of glycosylated L19-IL2
[0105] The L19-IL2 production process consists of a first upstream stage, dedicated to the cell culture of cells stably expressing L19-IL2, and a second downstream stage, dedicated to the recovery of the product by chromatographic purification.
[0106] In detail, the process consists of the following steps:
[0107] 1) Inoculum preparation (upstream 1),
[0108] 2) Fermentation (upstream 2),
[0109] 3) Purification (Downstream 1 and Downstream 2):
[0110] Affinity chromatography (downstream 1);
[0111] Cation exchange chromatography (CIEX) (downstream 2);
[0112] Buffer exchange (diafiltration) (downstream 2);
[0113] Preparation (downstream 2);
[0114] Anion exchange chromatography (AIEX) (downstream 2);
[0115] Nanofiltration (for virus removal) (downstream 2);
[0116] • Diafiltration (concentration) (downstream 2).
[0117] A process flow chart and detailed process description of these fabrication steps are presented herein.
[0118] Inoculum preparation (upstream 1) and fermentation (upstream 2)
[0119] Fig. 9A and Fig. 9B The figures shown in describe the inoculum preparation and fermentation process of L19-IL2 (upstream 1 and upstream 2). Upstream 1 and upstream 2 are divided into several numbered working steps, as reported in the following table.
[0120] Upstream 1 working step - Inoculum preparation
[0121]
[0122] Upstream 2 working steps - Fermentation process
[0123]
[0124] Inoculum preparation
[0125] A working cell bank vial of cells suitable for the production of L19-IL2 was first cultured in a T75 / T150 (cm2) containing 15-30 ml of culture medium under standard conditions (37°C, 5% CO2). 2 ) square flasks and then in 1.7 ml of medium containing 500 ml 2The cells were amplified in roller bottles (37°C, 0.75 rpm). The cell culture was amplified to a volume of up to 7 liters and to a cell concentration of more than 900.000 cells / ml with a vigor of more than 70%. CD hybridoma culture medium (ThermoFisher catalog number 11279023) supplemented with 4 mM glutamine was used for square flask cell culture, while 20 mM HEPES buffer was added for cell culture in roller bottles. At the end of the amplification, the cell suspension was transferred to a sterile bag using a peristaltic pump and connected to the bioreactor using an in-situ steam stainless steel connector.
[0126] Fermentation
[0127] Fermentation was carried out in a Biostat C 30L bioreactor, which was sterilized in situ and equipped with a gas mixer and annular sprinkler aeration system. pH was controlled by the addition of a CO2 stream and a calibrated sodium carbonate solution. The agitation system consisted of a single marine impeller. Temperature was controlled by a water jacket connected to a steam heat exchanger. The operating temperature was 37°C ± 0.01°C. The concentration of dissolved oxygen was maintained at 38% ± 2% air saturation value with a stream of air, nitrogen and oxygen mixture. The relative ratio of these three different gases was controlled by the gas mixer device of the bioreactor through the system management software. The partial pressure of the three gases was 0.95 atmospheres respectively. Cell culture aeration was carried out by using an annular sprinkler diffusion system. The maximum gas mixture flow rate was 1.1slpm ± 0.05. Before adding inoculum, the bioreactor was aseptically filled with 14L culture medium (CD hybridoma culture medium + 6mM Glutamax without protein and chemical composition). The culture medium contained in sterile plastic bags was transferred into the bioreactor vessel by gravity through an addition port assembly that was steam sterilized in situ. The fermentation process consisted of a semi-continuous cell adaptation period followed by a fed-batch fermentation.
[0128] Cell Adaptation
[0129] When inoculum (7L cell culture in sterile plastic bag) is added to the fresh medium in bioreactor, cell adaptation period begins.During this time period, glucose and L-super glutamine are added to cell culture at predetermined time intervals and concentrations.Stirring speed is set to 80 ± 5rpm.After 3-5 days, bioreactor is divided 1:4, harvest is discarded and replaced with fresh medium of same volume.After 3-5 days, cell culture is divided again, and the ratio this time is 1:5.4.2L cell culture is left in bioreactor, and 16.8L fresh medium is supplemented to reach the cumulative volume of 21L.This passage closes the cell adaptation period.At the end of the cell adaptation period, cell count reaches the viable cell concentration between 3-4,000,000 cells / ml usually, and the productivity is 30-40mg / L.The cell culture harvested during this stage is discarded without any further treatment.
[0130] Fed-batch fermentation
[0131] Fed-batch fermentation was started at the second cell culture split by adding 16.8 L of fresh medium to 4.2 L of cell culture used as inoculum at a dilution factor of 1:5. Agitation speed was set to 88 ± 5 rpm. Fed-batch fermentation lasted 10-11 days (depending on cell viability); during this period, the cell culture was fed with 35 g / L HyClone CellBoost 3 in Pro CHO5 medium and 200 mM L-ultraglutamine at regular intervals. Approximate feeding patterns are reported in the table below.
[0132]
[0133] During the fed-batch fermentation, the cell culture is sampled aseptically every day. At the end of the process, the total volume of the solution added is about 10-12L, so the cell culture of about 30-33L volume is harvested from the bioreactor. At the end of the fed-batch fermentation, the final harvest usually has about 5,000,000 viable cells / ml in the culture medium, and the productivity is about 150mg / L of secreted protein. Two paired bioreactors Biostat C 30L can also be used to carry out the above process. In this case, the 4.2L cell culture divided by 1:5 from the first bioreactor is used as the inoculum of the second bioreactor. Because the cells of the inoculum have adapted to the fermentation conditions, the second bioreactor does not need a semi-continuous cell adaptation period, and the fed-batch fermentation can be carried out simultaneously with the first bioreactor. At the end of the fed-batch fermentation, the crude harvest is collected, and the cells are removed by terminal filtration (see " microfiltration " below). The complete fermentation operation lasts for a total of 18 days, excluding the washing and sterilization of the equipment, and the two bioreactors produce a total harvest of about 60-65L. Typically, 8 to 10 g of crude harvest were obtained from one fermentation run.
[0134] Microfiltration
[0135] The crude harvest was clarified and sterilized by orthogonal filtration on disposable cartridge filters. Sartopure GF2, 0.65 μm, 0.6 m 2 The clarification step was performed using a cartridge filter, while further clarification and sterilization was performed using a combination of disposable Sartobran P, 0.45 / 0.22 μm, 0.45 μm 2 The harvested material was loaded into the filter with a peristaltic pump at a flow rate of 1-2 L / min. After filtration, 0.5 M EDTA solution pH 7.5 was added to the harvested material to reach a final EDTA concentration of 5 mM to obtain a clarified bulk material. The clarified bulk material was stored at 2°C-8°C for up to 40 days until the next purification step.
[0136] Purification (Downstream 1 and Downstream 2)
[0137] Fig. 10A and Fig. 10B The diagram shown in shows the purification process steps (Downstream 1 and Downstream 2) used to obtain L19-IL2.
[0138] Downstream 1 and Downstream 2 are divided into several numbered working steps as reported below.
[0139] Downstream 1 working step
[0140]
[0141] Downstream 2 working steps.
[0142]
[0143] The downstream 1 and downstream 2 steps require the preparation of several buffers for disinfection, equilibration, elution and washing of the column. Each buffer is prepared in a stainless steel tank under mechanical stirring and the pH is adjusted with 5M NaOH or 5M HCl. The buffer is then sterile filtered (through a Sartolon filter, 0.22 μm, 0.2 m2) and transferred to a sterile bag or bottle by a peristaltic pump.
[0144] Affinity chromatography on protein A (downstream 1)
[0145] Protein A affinity chromatography was performed using rmp agarose fast flow resin filled in Vantage A-130 or A-180 columns. rmp agarose fast flow resin is a low leakage, non-mammalian affinity resin designed for high purity separation of monoclonal and polyclonal antibodies. The base matrix (agarose 4 fast flow) is a highly cross-linked 4% agarose derivative containing five antigen binding domains. The scFv (L19) portion of the L19-IL2 fusion protein is bound to the protein A fixed on the resin. The difference between Vantage A-130 and Vantage A-180 columns is the volume of resin that can be filled into the column, which is 400mL to 700mL for Vantage A-130 and 700mL to 1300mL for Vantage A-180. Before loading the sample, the column, resin and flow line of the chromatographic system were sterilized in situ with a solution of acetic acid 0.1M / ethanol 20%. The contact time was 60 minutes. After treatment, the system was balanced in PBS (NaH2PO4·H2O 50mM; NaCl 150mM, EDTA 5mM, pH 7.5). Typically, 1000mL rmp agarose FF-Protein A resin was used with a Vantage 180 column. Up to 4.0g of crude L19-IL2, typically contained in 80-100L clarified batch material, was loaded onto the column at 100ml / min at room temperature. Immediately after loading the sample, the resin was washed at a flow rate of 150-200ml / min. The wash buffer and applied volume were:
[0146] -5.0L (5CV) PBS / NaCl (NaH2PO4·H2O 50mM; NaCl 650mM, EDTA 5mM, pH 7.5).
[0147] -5.0L (5CV) Gly / NaCl (glycine 100mM; NaCl 150mM, EDTA 5mM, pH 4.0)
[0148] The L19-IL2 fusion protein was then eluted from the column with Gly / NaCl (glycine 100mM; NaCl 150mM, EDTA 5mM, pH 3.0). The chromatographic run was performed by monitoring the absorbance, conductivity and pH at 280 and 260nm. The eluted sample was subjected to viral inactivation by incubation at room temperature at pH 3.0 for 1 hour. After incubation, glycerol was added to a final concentration of 1% w / v (conditioned) to obtain a semi-processed product. The OD (280nm) at this stage was between 1.0 and 1.7. The semi-processed product was stored at -80°C.
[0149] Cation Exchange Chromatography (CIEX) (Downstream 2)
[0150] The cation exchange chromatography step separates the major L19-IL2 isoforms: monomer, homodimer and trimer. The form of interest is represented by the non-covalent homodimeric form of L19-IL2. Before loading the sample on the column, the resin and flow lines of the chromatography system were sterilized in situ with a solution of sodium hydroxide 1 M for 60 minutes. After sterilization, the system was equilibrated in buffer "A" (Na2SO4 15mM; Na2HPO4·7H2O 15mM, EDTA 5mM, pH 6.00, 4.50-6.50mS / cm). Purification was performed on Source 30S packed in a VantageA2-60 column. The flow rate was 300cm / h, corresponding to 150ml / min. The semi-processed product was thawed in a water bath at room temperature. By diluting with conditioned solution (Na2SO4 100mM; Na2HPO4·7H2O 100mM, EDTA 5mM, pH 7.20, 23.50-27.50mS / cm) 4:5, followed by further dilution with water for injection 1:4, the ionic strength was adjusted to 5-6mS / cm. The pH was corrected to 6.00±0.10. The product was then filtered into a sterile plastic bag with a cartridge filter Sartobran P, 0.22μm, 0.05m2 (or 0.1m2 depending on volume) and loaded on the column at room temperature. The column was then washed with 2CV (2 liters) of buffer "A" (Na2SO4 15mM; Na2HPO4·7H2O 15mM, EDTA5mM, pH 6.00) at 150ml / min. Elution of the various L19-IL2 isoforms was performed at 150 ml / min with a continuous saline gradient using the following two buffer solutions: buffer "A" (Na2SO4 15 mM; Na2HPO4·7H2O 15 mM, EDTA 5 mM, pH 6.00, 4.50-6.50 mS / cm) and buffer "B" (NaCl 500 mM, Na2SO4 15 mM, Na2HPO4·7H2O 15 mM, EDTA 5 mM, pH 6.00, 44.0-48.0 mS / cm). The applied gradient can be divided into 2 different stages: 1: 0-40% B in 10 CV; and 2: 40%-100% B in 0 CV.
[0151] The various L19-IL2 isoforms (monomer, homodimer and trimer) were eluted at 9.5-14.0 mSi / cm (monomer), 15.0-19.0 mSi / cm (dimer), 19.0.-21.0 mSi / cm (trimer), respectively. The relative ratios of the various isoforms were generally in the range of 25%-35% monomer, 55%-65% homodimer and 3%-10% trimer. Considering the initial total amount of L19-IL2, the comprehensive yield of this step was 35%-45%, and considering only the initial amount of the homodimeric form of L19-IL2, the comprehensive yield of this step was higher than 75%. The purified homodimer of L19-IL2 (purified intermediate 1) was filtered through a 0.22 μm sterile filter in a glass bottle and stored at 2-8°C until the next process step. When all runs of the batch were completed, the purified intermediate 1 was pooled and then processed by buffer exchange.
[0152] Buffer exchange (downstream 2)
[0153] The buffer exchange process was performed using the Sartocon cartridge system (30 kDa), which is a tangential filtration system based on the membrane Hydrosart, based on hydrophilic and neutral cellulose, with a 30 kDa cut-off. This system allows the transfer of L19-IL2 into the formulation buffer using several diafiltration cycles. Before use, the cartridge was washed with a 0.9% NaCl solution for 10 minutes and sterilized with a NaOH 1M solution, recirculated for no less than 60 minutes at a pressure of 1.5 bar. After sterilization, the cartridge was washed with 1 L WFI and then equilibrated with formulation buffer (6.7 mM NaH2PO4, 1.8 mM KCl, 20 mM NaCl, 133 mM mannitol, 1% w / v glycerol, pH 6.30) until the pH and conductivity of the permeate matched the values of the formulation buffer. When the cartridge is equilibrated, diafiltration can be started. The permeate outlet is connected to the The UV / pH / conductivity monitor on the Pilot system is connected, and then the inlet and retentate outlet are connected to the three-way cap of the sample bottle. The third inlet of the sample bottle cap is connected to the buffer supply bottle. The purified intermediate 1 is passed through the cassette: the protein is retained and returned to the starting bottle (retentate), while the elution solution flows out as permeate. At the same time, the volume of permeate is replaced with an equal amount of formulation buffer. When the conductivity and pH of the retentate reach the same values as the formulation buffer, the buffer exchange is complete and a purified sample is obtained.
[0154] Preparation (downstream 2)
[0155] A solution of 0.1% v / v Tween 80 was then added to the purified sample. After this formulation step, the purified intermediate 2 was obtained (optical density comprised between 0.800 and 1.000).
[0156] Anion Exchange Chromatography (AIEX) (Downstream 2)
[0157] Anion exchange chromatography purification step was performed on Sartobind Q box. It is a strongly basic anion exchanger based on quaternary ammonium. Before loading the sample, the capsule was activated by pumping at least 200ml NaCl 1M, and then rinsed with NaOH 1M for at least 60 minutes to sterilize the capsule (provided as non-sterile). Sartobind Q capsules were used in flow-through mode so that L19-IL2 was not bound to the membrane and was directly collected in the flow-through container. DNA that may be present in the sample was removed by binding to the Sartobind Q matrix. This chromatogram obtained purified intermediate 3.
[0158] Nanofiltration (downstream 2)
[0159] The purpose of the nanofiltration process is to remove any viruses from the purified intermediate 3. Nanofiltration is performed using a Pro Modus 1.1 or ProModus 1.2 Viresolve filter. The filter is rinsed with water for 10 minutes, sterilized by flushing with NaOH 0.5M for 1 hour, and then equilibrated with formulation buffer. The Pilot system automatically adjusted the filtration flow rate to maintain a constant pressure. The filtered material represented purified intermediate 4 with an optical density between 0.800 and 1.000.
[0160] Diafiltration (downstream 2)
[0161] The purpose of the diafiltration process is to concentrate the purified intermediate 4 to reach an optical density between 2.100 and 2.400. A 30 kDa Sartocon cartridge system is used for concentration. The system can concentrate the purified intermediate 4 through several diafiltration cycles; in this case, the concentration factor is about 3. During this process, the formulation buffer filtered through the cartridge is not changed (permeate), while the protein is retained and returned to the starting bottle (retentate). Before use, the cartridge is washed with 0.9% NaCl solution for 10 minutes and disinfected with NaOH 1M solution, recirculating for at least 60 minutes at 1.5 bar pressure. After disinfection, the cartridge is washed with 1 L WFI and then equilibrated with formulation buffer until the pH and conductivity of the permeate match the values of the formulation buffer. When the cartridge is equilibrated, concentration can be started. The permeate outlet is connected to The UV / pH / conductivity monitor on the Pilot system was connected, and then the inlet and retentate outlet were connected to the three-way cap of the sample bottle. The A280nm of the retentate was checked during the process; the concentration process was stopped when the A280nm reached a value of 2.250±0.150. The purified batch material obtained at the end of this process represents the drug substance. During this concentration step, the excipient polysorbate 80 was also concentrated to 0.3% v / v.
[0162] Example 2 - Method for producing a L19-IL2 preparation containing a high percentage of glycosylated L19-IL2 (not based on claimed invention; included for comparison purposes only)
[0163] L19-IL2 was expressed by transient gene expression using the mammalian expression vector pcDNA3-L19-IL2 according to standard methods described below (ie, not according to the claimed invention).
[0164] For 1 ml of production, 4 × 10 6 Cells were transfected and resuspended in 1 mL of medium supplemented with 4 mM superglutamine. 0.75 μg of plasmid DNA per million cells was added to the cells, followed by 2.5 μg of polyethyleneimine (PEI; 1 mg / mL solution in water, pH 7.0) and gently mixed. The transfected cultures were incubated in a shaking incubator at 31°C for 6 days.
[0165] L19-IL2 was then purified by protein A affinity chromatography followed by a polishing step by cation exchange chromatography (CIEX). Briefly, six-day supernatants from transfected cells were clarified by centrifugation and filtration and then purified using PURE Chromatography System Loaded into HiTrap TM rProtein A fast flow column. The column was washed by 5 consecutive steps consisting of: (1) 150 mM NaCl, 50 mM NaH2PO4, 5 mM EDTA, 50 mM NaOH, pH 7.5; (2) 650 mM NaCl, 50 mM NaH2PO4, 5 mM EDTA, 53 mM NaOH, pH 7.5; (3) 50 mM NaH2PO4, 150 mM NaCl, 1 M urea, 5 mM EDTA, 10% (v / v) isopropanol, pH 7.5; (4) 250 mM L-arginine, pH 7.5; (5) 50 mM citric acid (pH 4), and then the L19-IL2 sample was eluted with 50 mM citric acid (pH 4).
[0166] The collected eluate was then further purified by CIEX using Source 30S resin as the solid support.
[0167] In brief, the L19-IL2 sample purified by protein A was conditioned by diluting with 2.5 volumes of MilliQ-H2O and 1.15 volumes of 100mM Na2SO4, 100mM Na2HPO4, 5mM EDTA (pH 7.2), and then loaded on Source30S column. Then the L19-IL2 loaded by 0-40% gradient elution from buffer A (15mM Na2SO4, 15mM Na2HPO4, 5mM EDTA, pH 6) to buffer B (15mMNa2SO4, 15mM Na2HPO4, 5mM EDTA, 0.5M NaCl, pH 6) was used. Finally, the refined L19-IL2 sample was aliquoted, snap frozen in liquid nitrogen and stored at -80°C until further use.
[0168] Example 3 - Quality Control of L19-IL2
[0169] Several quality control analyses were used to characterize the purity of the L19-IL2 batches prepared according to Example 1, including ELISA, SDS-PAGE, size exclusion chromatography, A 280 Measurements, productivity, bioactivity and immunoreactivity determinations, osmolarity, virus testing, visual appearance, etc. The protocol used for 2D-SDS-PAGE analysis is reported below.
[0170] 2D-SDS-PAGE
[0171] Use prefabricated systems ( IPGRunner TM ) Each sample was analyzed in a two-dimensional electrophoresis assay. Proteins were separated based on their molecular weight and isoelectric point. Blue Coomassie R-250 was used for staining. The results are reported in Figure 2.
[0172] Example 4 - Mass Spectrometry Analysis of L19-IL2
[0173] Direct Infusion HR-MS for Intact Mass Analysis
[0174] 100 μg of each L19-IL2 sample was desalted using C18 purification prior to analysis (micro spin columns, Harvard Apparatus). Direct infusion was performed on an Orbitrap Q-Exactive coupled to an Ion Max ESI source. The following parameters were used: syringe flow rate 4 μL / min, capillary voltage 3.0 kV, in-source induced dissociation 40 eV, sheath gas 4 units, capillary temperature 300°C, S-lens RF level 90, resolution 17500 (FWHM at 200 m / z), AGC target 5 x 10 4, microscan 10, mass range 500-3000 m / z, and maximum injection time 200 ms. The raw spectra were then analyzed to quantify the relative amounts of glycosylated and non-glycosylated L19-IL2 to total L19-IL2 in the formulation. Quantification was achieved by summing the intensities of the peaks corresponding to glycosylated and non-glycosylated L19-IL2 species, and the percentages were calculated using the following equation.
[0175]
[0176] Where x is the sum of the intensities of the individual L19-IL2 variants (non-glycosylated, HexNAc1Hex1NeuGc1 glycosylated, or HexNAc1Hex1NeuGc2 glycosylated). The results of this analysis are reported in Figures 3 and 4. These figures illustrate the percentage of glycosylated L19-IL2 in the formulations prepared according to the methods described herein ( Figure 3A and Figure 4A ) was significantly lower than the percentage of glycosylated L19-IL2 in the preparation prepared according to the standard method ( Figure 3B and Figure 4B ).
[0177] MS / MS analysis for glycopeptide analysis
[0178] 7.5 μg L19-IL2 was resuspended in 1M urea dissolved in NH4HCO3 solution (final pH = 8). The protein was reduced with TCEP for 15 min at room temperature, then reduced at 65 ° C for 45 min, and alkylated with iodoacetamide (IAA) for 1 hour in the dark. The protein was then digested overnight at 37 ° C with trypsin (enzyme-protein ratio 1: 60). After digestion, the sample was acidified with 10% formic acid, followed by C18 purification and desalting (small centrifugal column, Harvard Apparatus). 500ng of the resulting peptides were then subjected to HPLC-MS / MS analysis. All samples were analyzed on an Orbitrap Q-Exactive mass spectrometer coupled to an EASY nanoLC 1000 system via a Nano Flex ion source. The peptides were purified by HPLC-MS / MS analysis using an Acclaim PepMap RSLC column (50 μm x15 cm, particle size 2 μm, pore size ) and chromatographic separation was performed at a flow rate of 300 nL / min using a linear gradient of 5%-35% solvent B (0.1% formic acid in acetonitrile) over 40 min. Ionization was performed in positive ion mode with a spray voltage of 2 kV, a capillary temperature of 250°C, and an S-lens RF level of 60. The mass spectrometer was operated in data-dependent mode. The MS1 scan range was set to 350 to 1650 m / z, and the 10 most abundant peptides were subjected to HCD fragmentation with an NCE of 25. Dynamic exclusion was set to 10 seconds. The raw files were processed with Proteome Discoverer 1.4. Database searches were performed using Sequest as the search engine using FASTA files containing the target protein, the mus musculus reference proteome, and additional contaminants (human keratin isoforms, bovine serum albumin, and protein A from Staphylococcus Aureus). Carbamidomethylation of cysteine was set as a fixed modification, while oxidation and different O-glycosylation of methionine (HexNAc1Hex1NeuGc1, HexNAc1Hex1NeuGc2) were set as variable modifications. Trypsin was set as cleavage specificity, allowing up to 2 missed cleavages. Data filtering was performed using a percolator, resulting in a 1% false discovery rate (FDR). The results of this analysis are shown in Figures 5 to 8 middle.
[0179] Example 5-CTLL2 T cell activity assay
[0180] To show the effect of glycosylation levels on T cell activation activity, formulations containing a high percentage of glycosylated L19-IL2 were compared to formulations containing a low percentage of glycosylated L19-IL2 in a T cell proliferation assay. The assay is based on a colorimetric method for determining the number of viable cells in proliferation.
[0181] Cell culture
[0182] The CTLL-2 cell line is a clone of cytotoxic T cells whose growth is IL2-dependent and which is routinely used to determine the activity of IL2 and IL2 conjugates such as L19-IL2. CTLL2 cells are grown in RPMI-1640 culture medium (Gibco; 21875-034) supplemented with 10% FBS and 2mM L-glutamine. Fresh 10% T-STIM containing ConA is added at each passage. Cells are cultured in 20mL culture medium in a T-75 flask maintained at 37°C and 5% CO2. Cells are maintained at a density between 0.1-0.5mio / mL.
[0183] Day 1:
[0184] Step 1: Count cells (eg, 0.4 mio / mL of 20 mL), spin at 900 rpm for 5 minutes, then wash with 50 mL of media.
[0185] Step 2: Spin cells at 900 rpm for 5 minutes and then wash with 50 mL of culture medium.
[0186] Step 3: Spin the cells at 900 rpm for 5 minutes and then resuspend in 20 mL of culture medium at the initial concentration.
[0187] Step 4: Incubate the cells at 37°C and 5% CO2 for 24 hours.
[0188] Day 2:
[0189] Step 1: Spin cells at 900 rpm for 5 minutes and then wash with 50 mL of culture medium.
[0190] Step 2: Spin the cells at 900 rpm for 5 minutes and then resuspend in culture medium at a concentration of 0.5 mio / mL.
[0191] Step 3: Add 50 μL of cells per well of a 96-well plate (ie, 25'000 cells / well).
[0192] Step 4: Add 50 μL of protein sample diluted in culture medium according to the serial dilution scheme to each well.
[0193] Step 5: Incubate the cells at 37°C and 5% CO2 for 48 hours.
[0194] Day 4:
[0195] Step 1: Add 20 μL of CellTiter Aqueous One solution to each well and incubate the cells at 37°C and 5% CO2.
[0196] Step 2: Measure the absorbance at 490 nm and 620 nm at the following time points: 1 h, 2 h, 3 h and 4 h.
[0197] Data normalization:
[0198] Step 1: Subtract the medium-only background from the absorbance data of all samples.
[0199] Step 2: Normalize the data using the following formula: (sample - mean cells only) / mean cells only.
[0200] result:
[0201] The results of this assay are shown in Fig.11This indicates that the L19-IL2 preparation containing a low percentage of glycosylated L19-IL2 exhibited superior T cell activation activity (EC50 4.3 pM) as compared to the L19-IL2 preparation containing a high percentage of glycosylated L19-IL2 (EC50 9.5 pM).
[0202] Sequence Listing
[0203] Amino acid sequence of L19 CDR
[0204] L19 CDR1 VH-SFSMS (SEQ ID NO:1)
[0205] L19 CDR2 VH-SISGSSGTTYYADSVKG (SEQ ID NO:2)
[0206] L19 CDR3 VH-PFPYFDY (SEQ ID NO:3)
[0207] L19 CDR1 VL-RASQSVSSSFLA (SEQ ID NO:4)
[0208] L19 CDR2 VL-YASSRAT (SEQ ID NO:5)
[0209] L19 CDR3 VL-QQTGRIPPT (SEQ ID NO:6)
[0210] Amino acid sequence of L19 VH domain (SEQ ID NO:7)
[0211] EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSS
[0212] Amino acid sequence of the linker between VH and VL (SEQ ID NO: 8)
[0213] GDGSSGGSGGAS
[0214] Amino acid sequence of L19 VL domain (SEQ ID NO: 9)
[0215] EIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK
[0216] Amino acid sequence of L19scFv (SEQ ID NO: 10)
[0217] EVQLLESGGGLVQPGGSLRLSCAASGFTFSSFSMSWVRQAPGKGLEWVSSISGSSGTTYYADSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCAKPFPYFDYWGQGTLVTVSSGD GSSGGSGGASEIVLTQSPGTLSLSPGERATLSCRASQSVSSSFLAWYQQKPGQAPRLLIYYASSRATGIPDRFSGSGSGTDFTLTISRLEPEDFAVYYCQQTGRIPPTFGQGTKVEIK
[0218] Amino acid sequence of human interleukin 2 (huIL-2) (SEQ ID NO: 11).
[0219] Threonine 3 is shown in bold, italic and underlined
[0220]
[0221] Amino acid sequence of the linker between scFv and IL2 (SEQ ID NO: 12)
[0222] EFSSSSGSSSSGSSSSG
[0223] Amino acid sequence of L19-IL2 conjugate (SEQ ID NO: 13)
[0224] Threonine 256 is shown in bold, italic and underlined
[0225]
[0226] Amino acid sequence of L19-huTNFα conjugate (SEQ ID NO: 14)
[0227] Serine 257 is shown in bold, italic and underlined
[0228]
[0229]
Claims
1. A pharmaceutical preparation, comprising: (i) non-glycosylated L19-IL2; and (ii) glycosylated L19-IL2; The L19-IL2 comprises or consists of the sequence shown in SEQ ID NO: 13, and the percentage of glycosylated L19-IL2 in the preparation is ≤ 20% of the total L19-IL2. 2 . The pharmaceutical formulation according to claim 1 , wherein the glycosylated L19-IL2 comprises O-linked glycosylation on the threonine at position 256 of SEQ ID NO:
13.
3. The pharmaceutical formulation according to claim 2, wherein the O-linked glycosylation consists of HexNAc1Hex1NeuGc1 or HexNAc1Hex1NeuGc2.
4. The pharmaceutical preparation according to any one of claims 1 to 3, further comprising a pharmaceutically acceptable excipient, a carrier, a buffer, a stabilizer.
5. The pharmaceutical formulation according to any one of claims 1 to 4, for use in a method of treating cancer in a patient.
6. The pharmaceutical formulation for use according to claim 5, wherein the cancer is skin cancer, kidney cancer, pancreatic cancer, non-small cell lung cancer, diffuse large B-cell lymphoma (DLBCL), basal cell carcinoma or cutaneous squamous cell carcinoma.
7. The pharmaceutical formulation for use according to claim 5 or 7, wherein the method comprises administering a second anti-cancer therapeutic agent to the patient.
Citation Information
Patent Citations
Polymeric ultraviolet light stabilisers containing hindered alkyl amines and polymer compositions containing them
EP0002022A1
Drugs containing a glycosylated interleukin-2
US5417970A
Specific binding molecules for scintigraphy, conjugates containing them and therapeutic method for treatment of angiogenesis
US8097254B2
Compositions and methods for treatment of angiogenesis in pathological lesions
WO2001062298A2
Combination of an Anti-edb fibronectin domain antibody / il2 fusion protein and a further small molecule
WO2007115837A2
